DVRd Improves MRD Negativity and PFS in Transplant-Ineligible Myeloma

This is a subgroup analysis of the phase III CEPHEUS trial focusing on transplant-ineligible or transplant-deferred patients with newly diagnosed multiple myeloma (N=289). The trial reported that adding daratumumab to bortezomib, lenalidomide, and dexamethasone (DVRd) resulted in higher MRD negativity rates (60.4% vs 39.3%) and sustained MRD negativity compared with VRd alone, along with a 49% lower risk of disease progression or death (HR 0.51). The trial authors state that adverse events were consistent with known safety profiles and that the findings reinforce DVRd as a standard of care in this population.

Most relevant for: Patients with newly diagnosed multiple myeloma who are ineligible for or deferring autologous stem cell transplantation.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.